(Q44527882)

3 December 2017

Treatment of congenital nephrogenic diabetes insipidus by hydrochlorothiazide and cyclooxygenase-2 inhibitor (English)

1 reference

nephrogenic diabetes insipidus

3 December 2017

1 reference

1 reference

2

Uri S Alon

1 reference

3 December 2017

Anirut Pattaragarn

1

1 reference

PubMed ID

12883974

3 December 2017

language of work or name

1 reference

18 July 2003

1 reference

3 December 2017

1 reference

3 December 2017

18

1 reference

3 December 2017

10

1 reference

3 December 2017

1073-1076

1 reference

https://scigraph.springernature.com/pub.10.1007/s00467-003-1195-0

3 December 2017

0 references

cites work

Antidiuretic hormone increases renal prostaglandin synthesis in vivo

1 reference

12 December 2020

Effect of meclofenamate or ketoconazole on the natriuretic response to increased pressure

1 reference

12 December 2020

Natriuretic response to increased pressure is preserved with COX-2 inhibitors

1 reference

12 December 2020

Clinical presentation and follow-up of 30 patients with congenital nephrogenic diabetes insipidus

1 reference

12 December 2020

Effect of hydrochlorothiazide and indomethacin treatment on renal function in nephrogenic diabetes insipidus

1 reference

12 December 2020

Acute renal dysfunction associated with selective COX-2 inhibitor therapy

1 reference

12 December 2020

The effect of inhibition of prostaglandin synthesis on free water and osmolar clearances in patients with hereditary nephrogenic diabetes insipidus

1 reference

12 December 2020

Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine

1 reference

12 December 2020

Hydrochlorothiazide-amiloride in the treatment of congenital nephrogenic diabetes insipidus

1 reference

12 December 2020

Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition

1 reference

12 December 2020

Hydrochlorothiazide, amiloride and tolmetin in the treatment of diabetes insipidus of Brattleboro rats

1 reference

12 December 2020

Molecular and cellular defects in nephrogenic diabetes insipidus

1 reference

12 December 2020

Colocalization of the gene for nephrogenic diabetes insipidus (DIR) and the vasopressin type 2 receptor gene (AVPR2) in the Xq28 region

1 reference

12 December 2020

Comparative analgesia, cardiovascular and renal effects of celecoxib, rofecoxib and acetaminophen (paracetamol).

1 reference

12 December 2020

Amiloride-hydrochlorothiazide versus indomethacin-hydrochlorothiazide in the treatment of nephrogenic diabetes insipidus

1 reference

12 December 2020

Cognitive and psychosocial functioning of patients with congenital nephrogenic diabetes insipidus.

1 reference

12 December 2020

New insights into the paradoxical effect of thiazides in diabetes insipidus therapy

1 reference

12 December 2020

Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis

1 reference

12 December 2020

Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects

1 reference

12 December 2020

Cyclooxygenase-2 inhibition and renal physiology

1 reference

12 December 2020

THE MECHANISM OF ANTIDIURESIS ASSOCIATED WITH THE ADMINISTRATION OF HYDROCHLOROTHIAZIDE TO PATIENTS WITH VASOPRESSIN-RESISTANT DIABETES INSIPIDUS

1 reference

12 December 2020

Nephrotic syndrome and interstitial nephritis associated with celecoxib

1 reference

12 December 2020

Tolmetin sodium in the management of nephrogenic diabetes insipidus

1 reference

12 December 2020

Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects?

1 reference

12 December 2020

Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity

1 reference

12 December 2020

10.1007/S00467-003-1195-0

Identifiers

DOI

1 reference

3 December 2017

1 reference

PubMed ID

12883974